The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.

Johnson & Johnson halted the limited rollout of its Varipulse pulsed field ablation system on Jan. 5 to “investigate the root causes of four reported neurovascular events in the U.S. external ...

Quantum computing stocks are having a tumultuous week, but one fund manager says investors should focus on the long game when ...

Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA ...

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad ...

Johnson & Johnson (NYSE:JNJ) has received Priority Review designation from the FDA for the Biologics License Application for ...

Johnson & Johnson said on Wednesday it temporarily paused the rollout of its Varipulse heart device in the United States as ...

Johnson & Johnson announced the nipocalimab Biologics License Application received Priority Review designation from the U.S Food and Drug ...

J&J's MedTech unit pauses all cases of the Varipulse PFA system as part of an external evaluation. Stock dips.

Despite the pause, the company clarified that the suspension does not impact commercial activity outside the US.